From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
Overall | Cohort | |||||||
---|---|---|---|---|---|---|---|---|
HER2-negative (N = 9) | HER2-positive (N = 29) | |||||||
Grade | Grade | |||||||
N | 1 | 2 | 3 | 1 | 2 | 3 | 4 | |
AE name | ||||||||
Hemoglobin | 29 (76%) | 4 (44%) | 3(33%) | 10 (34%) | 11 (38%) | 1 (3%) | ||
Fatigue | 28 (74%) | 1 (11%) | 3(33%) | 2(22%) | 9 (31%) | 9 (31%) | 4 (14%) | |
Platelets | 28 (74%) | 3 (33%) | 3(33%) | 6 (21%) | 12 (41%) | 3 (10%) | 1 (3%) | |
AST | 23 (61%) | 5 (56%) | 1(11%) | 15 (52%) | 2 (7%) | |||
22 (58%) | 2 (22%) | 1(11%) | 3 (10%) | 13 (45%) | 3 (10%) | |||
Head/headache | 20 (53%) | 4 (44%) | 10 (34%) | 6 (21%) | ||||
Hyperglycemia | 18 (47%) | 3 (33%) | 1(11%) | 12 (41%) | 2 (7%) | |||
Leukocytes | 18 (47%) | 4 (14%) | 14 | |||||
Nausea | 17 (45%) | 1 (11%) | 1(11%) | 13 (45%) | 2 (7%) | |||
ALT | 14 (37%) | 3 (33%) | 1(11%) | 8 (28%) | 2 (7%) | |||
Constipation | 14 (37%) | 3(33%) | 1(11%) | 7 (24%) | 3 (10%) | |||
Neuropathy-sensory | 14 (37%) | 3(33%) | 9 (31%) | 2 (7%) | ||||
Nose, hemorrhage | 12 (32%) | 1(11%) | 9 (31%) | 2 (7%) | ||||
Alkaline phosphatase | 11 (29%) | 9 (31%) | 2 (7%) | |||||
Diarrhea w/o prior colostomy | 11 (29%) | 1(11%) | 1(11%) | 7 (24%) | 2 (7%) | |||
Cough | 9 (24%) | 8 (28%) | 1 (3%) | |||||
Hypertension | 9 (24%) | 6 (21%) | 2 (7%) | 1 (3%) | ||||
Alteration in bone age | 8 (21%) | 6 (21%) | 2 (7%) | |||||
Proteinuria | 8 (21%) | 1(11%) | 6 (21%) | 1 (3%) | ||||
Extremity-limb, pain | 7 (18%) | 4 (14%) | 2 (7%) | 1 (3%) | ||||
Alopecia | 6 (16%) | 1(11%) | 4 (14%) | 1 (3%) | ||||
Hyponatremia | 6 (16%) | 5 (17%) | 1 (3%) | |||||
Joint, pain | 6 (16%) | 3 (10%) | 2 (7%) | 1 (3%) | ||||
Vomiting | 6 (16%) | 2(22%) | 1(11%) | 2 (7%) | 1 (3%) | |||
Allergic reaction | 5 (13%) | 1 (3%) | 4 (14%) | |||||
Back, pain | 5 (13%) | 4 (14%) | 1 (3%) | |||||
Dizziness | 5 (13%) | 2 (7%) | 3 (10%) | |||||
Infection Grade 0–2, upper airway | 5 (13%) | 4 (14%) | 1 (3%) | |||||
Left ventricular systolic dysfunction | 5 (13%) | 5 (17%) | ||||||
Pain-other | 5 (13%) | 1(11%) | 1(11%) | 1 (3%) | 2 (7%) | |||
Rectum, hemorrhage | 5 (13%) | 4 (14%) | 1 (3%) | |||||
Bone, pain | 4 (11%) | 4 (14%) | ||||||
CNS, hemorrhage | 4 (11%) | 1(11%) | 1(11%) | 2 (7%) | ||||
Constitutional, other | 4 (11%) | 3 (10%) | 1 (3%) | |||||
Creatinine | 4 (11%) | 2(22%) | 2 (7%) | |||||
GI-other | 4 (11%) | 4 (14%) | ||||||
Hypocalcemia | 4 (11%) | 4 (14%) | ||||||
Hypokalemia | 4 (11%) | 1(11%) | 3 (10%) | |||||
Metabolic/laboratory-other | 4 (11%) | 2(22%) | 1(11%) | 1 (3%) | ||||
Skin-other | 4 (11%) | 2(22%) | 1 (3%) | 1 (3%) | ||||
Throat/pharynx/larynx, pain | 4 (11%) | 4 (14%) |